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SUPPORTING FIGURES
Figure S1
Biocompatibility of MCNPs in glioblastoma cells
Figure S2
Biocompatibility of MCNPs in MDA-MB-231cells
Figure S3
Biocompatibility of MCNP-PEI constructs in U87-vIII and MDA-MB-231 cells
Figure S4
Effect on cell viability of ATAP in DMSO
Figure S5
Optimization of magnetic-field exposure time for MCNP-ATAP constructs
Figure S6
Percent cell viability of cleavable and non-cleavable MCNP-ATAP constructs
Figure S7
Percent cell viability of MCNP-ATAP constructs combined with water-bath hyperthermia in brain cancer cells.
Figure S8
Effect of duration of MCNP-mediated hyperthermia on the viability of U87vIII and MDA-MB-231 cells
Figure S9
Effect of ATAP in DMSO on mitochondrial membrane permeabilization Figure S1: Biocompatibility of MCNPs in glioblastoma cells. The percentage of viable cells was estimated using MTS assay following incubation of cells with the MCNPs for 48 h. The data was obtained as absorbance of water-soluble formazan at 490 nm in the MCNP-treated cells, normalized to that of untreated controls. All measurements were done in triplicates and the results represent mean ± standard error of mean. Figure S5: Effect of magnetic field exposure on the uptake of MCNP constructs. The MCNPs were coated with PEI first and then labeled with Alexa-Fluor 594. The U87vIII were incubated with 10 ug/mL MCNPs and exposed to a static magnetic field for increasing periods of time (15-60 min). Following this, the cells were washed with cold PBS and replaced with fresh growth medium. The uptake of MCNPs was measured using fluorescence microscopy. Figure S11 : Preliminary in vivo studies of ATAP-iRGD constructs in a mouse model of esophageal cancer. ATAP-iRGD suppresses esophageal tumor growth with limited off-target toxicity in the mouse model. Esophageal cancer cells KYSE-150 were injected subcutaneously into both flanks of nude mice and allowed to establish tumors. Xenograft model showed that ATAP-iRGD had similar tumor suppression effects as BH3-iRGD peptide (equal molar concentration). Both ATAP-iRGD and BH3-iRGD treatment significantly reduced tumor size and weight (A, B, D), without apparent toxicity and showing no significant difference between the body weights of these three groups (C). Based on MTS assay, the IC 50 for ATAP-iRGD is determined in the range of 1-5 µM in different cancer type (De et al, 2014) . After MCNP packaging of ATAP, we found that MCNP-ATAP remarkably improved the IC 50 from the µM range to 50-100 nM range. This shows that utilization of MCNP could enhance the delivery of ATAP to tumor cells.
